REGENXBIO, Inc. (RGNX)
7.23
+0.05
(+0.70%)
USD |
NASDAQ |
Nov 20, 10:10
REGENXBIO Cash from Operations (Quarterly) : 38.61M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 38.61M |
| June 30, 2026 | -62.24M |
| March 31, 2026 | -76.19M |
| December 31, 2025 | -52.29M |
| September 30, 2025 | -55.96M |
| June 30, 2025 | -49.34M |
| March 31, 2025 | 33.63M |
| December 31, 2024 | -31.62M |
| September 30, 2024 | -40.55M |
| June 30, 2024 | -45.50M |
| March 31, 2024 | -55.46M |
| December 31, 2023 | -40.76M |
| September 30, 2023 | -49.41M |
| June 30, 2023 | -47.32M |
| March 31, 2023 | -80.92M |
| December 31, 2022 | -39.37M |
| September 30, 2022 | -50.46M |
| June 30, 2022 | -61.75M |
| March 31, 2022 | -55.91M |
| December 31, 2021 | 326.24M |
| September 30, 2021 | -36.36M |
| June 30, 2021 | -29.87M |
| March 31, 2021 | -41.13M |
| December 31, 2020 | 39.47M |
| September 30, 2020 | -36.46M |
| Date | Value |
|---|---|
| June 30, 2020 | -21.50M |
| March 31, 2020 | -35.57M |
| December 31, 2019 | -25.51M |
| September 30, 2019 | -29.15M |
| June 30, 2019 | -23.75M |
| March 31, 2019 | -29.30M |
| December 31, 2018 | -4.14M |
| September 30, 2018 | -19.56M |
| June 30, 2018 | 70.21M |
| March 31, 2018 | 58.13M |
| December 31, 2017 | -13.83M |
| September 30, 2017 | -17.14M |
| June 30, 2017 | -9.549M |
| March 31, 2017 | -17.48M |
| December 31, 2016 | -20.42M |
| September 30, 2016 | -11.82M |
| June 30, 2016 | -8.43M |
| March 31, 2016 | -7.887M |
| December 31, 2015 | -4.443M |
| September 30, 2015 | -8.361M |
| June 30, 2015 | -8.002M |
| March 31, 2015 | -1.675M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AbbVie, Inc. | 7.606B |
| Anika Therapeutics, Inc. | 8.377M |
| United Therapeutics Corp. | 306.50M |
| Biomea Fusion, Inc. | -8.433M |
| ACADIA Pharmaceuticals, Inc. | 11.50M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -86.15M |
| Cash from Financing (Quarterly) | 106.85M |
| Free Cash Flow | -154.80M |
| Free Cash Flow Per Share (Quarterly) | 0.5886 |
| Free Cash Flow to Equity (Quarterly) | 36.65M |
| Free Cash Flow to Firm (Quarterly) | 45.89M |
| Free Cash Flow Yield | -32.38% |